Abstract
We have measured the serum concentration of prostate specific antigen (tPSA) and determined the percent free PSA (% fPSA) in serial specimens from 64 patients with prostate cancer, 35 patients with benign prostate hyperplasia (BPH), and 3 patients with prostitis. We found that the % fPSAs were not a constant for individual patients during the course of the disease. When we compared only the % fPSA of the first specimen of serial specimens from individual patients, who were largely untreated, 37% of BPH specimens were above 22%, whereas only 1.6% cancer samples were above that value. We also found that 67% of cancer specimens and 14% of BPH samples were below 8%, respectively. Although % fPSA distribution pattern remained similar between two types of specimens, less differentiation was found between BPH and prostate cancer in random specimens compared to the study using first specimens of an individual patient's serial samples. Percent fPSA apparently are affected by treatment. However, the most important benefit for the determination of % fPSA appears to be the sensitivity of % fPSA to identify occult tumors when the tPSAs were in the normal concentration range. Determination of % fPSA also seems to improve the specificity of tPSA, not only during screening for the differentiation between BPH and prostate cancer, but also during monitoring of treatment and recurrence. J. Clin. Lab. Anal. 12:26–31, 1998. © 1998 Wiley‐Liss, Inc.
Keywords: BPH, benign prostate hyperplasia, prostate cancer
References
- 1. Wu JT: Assay for prostate specific antigen (PSA): Current problems and possible solutions. J Clin Lab Anal 8: 51–62, 1994. [DOI] [PubMed] [Google Scholar]
- 2. Wu JT: Serum prostate specific antigen assay — An update. Western J Med (Epitomes‐Pathology) 162: 447–148, 1995. [PMC free article] [PubMed] [Google Scholar]
- 3. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923, 1991. [DOI] [PubMed] [Google Scholar]
- 4. Lilja H, Cockett ATK, Abrahamsson P‐A: Prostate specific antigen predominantly forms a complex with alphal‐antichymotrypsin in blood. Cancer Supplement 70: 230–234, 1992. [DOI] [PubMed] [Google Scholar]
- 5. Wu JT, Zhang P, Wang T, et al.: Evaluation of free PSA isoforms, PSA complex formation and specificity of anti‐PSA antibodies by HPLC and PAGE‐immunoblotting techniques. J Clin Lab Anal 9: 1–14, 1995. [DOI] [PubMed] [Google Scholar]
- 6. Wu JT, Wilson L, Zhang P, Meikle WA, Stephenson RA: Correlation of serum concentrations of PSA‐ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 9: 15–20, 1995. [DOI] [PubMed] [Google Scholar]
- 7. Catalona W, Smith D, Ratliff T, et al.: Measurement of prostate‐specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156–1161, 1991. [DOI] [PubMed] [Google Scholar]
- 8. Catalona WJ, Smith DS, Wolfert RL, et al.: Evaluation of percentage of free serum prostate‐specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220, 1995. [PubMed] [Google Scholar]
- 9. Vashi AR, Oesterling JE: Percent free prostate‐specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin Proc 72: 337–334, 1997. [DOI] [PubMed] [Google Scholar]
- 10. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011–1017, 1989. [DOI] [PubMed] [Google Scholar]
- 11. Catalona WJ, Colberg JW, Smith DS, et al.: Measurement of percent‐free PSA improves specificity for lower PSA cutoffs in prostate cancer screening. J Urol 155: 422A, 1996. [Google Scholar]
- 12. Wu JT, Stephenson RA: Microplate assays for free PSA, PSA‐ACT and total PSA Microplate assays for free PSA, PSA‐ACT and total PSA: Assay characteristics, selection of calibrators and in vitro stability studies. Proceeding of the 1st International Consultation on Prostate Cancer, 1997, p 159–168.
- 13. Chan DW, Bruzek DJ, Oesterling JE, et al.: Prostate‐specific antigen as a marker for prostate cancer: A monoclonal and a polyclonal immunoassay compared. Clin Chem 3: 1916–1920, 1987. [PubMed] [Google Scholar]
- 14. van Duijnhoven HLP, Pequeriaux NCV, van Zon John PHM, Blankenstein MA: Large discrepancy between prostate‐specific antigen results from different assays during longitudinal follow‐up of a prostate cancer patient. Clin Chem 42: 637–641, 1996. [PubMed] [Google Scholar]
- 15. Oesterling JE, Jacobsen SJ, Chute CG, et al.: Serum prostate‐specific antigen in a community‐based population of healthy men: Establishment of age‐specific reference ranges. JAMA 270: 860–864, 1993. [PubMed] [Google Scholar]
- 16. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age‐specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153: 1160–1163, 1995. [PubMed] [Google Scholar]
- 17. Babaian RJ, Camps JL, Frangos DN, et al.: Monoclonal prostate‐specific antigen in untreated prostate cancer: Relationship to clinical stage and grade. Cancer 67: 2200–2206, 1991. [DOI] [PubMed] [Google Scholar]
- 18. Kojima M, Babaian RJ: Algorithms for early detection of prostate cancer: Current state of the “art”. Cancer 75: 1860–1868, 1995. [Google Scholar]
- 19. Murphy GP, Barren RJ, Erickson SJ, et al.: Evaluation and comparison of two new prostate carcinoma markers: Free‐prostate specific antigen and prostate specific membrane antigen. Cancer 78; 809–818, 1996. [DOI] [PubMed] [Google Scholar]